Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked vigilantly but unsuccessfully to develop an one-time therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the last several shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire interview that I came away with a bad viewpoint of the business.

Irony of irony, my bad impression of the business enterprise has grown steadily, yet the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment and avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the know-how as well as connected intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) along with the first new drug application endorsement ($5 million), and even royalty payments of 5 percent of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it has this single treatments in addition to a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an active business with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple publications in addition to multiple delivering presentations.

Could all this be smoke cigarettes and mirrors? That is a question I have been asking myself with the very beginning of the interest of mine in this particular business. Judging by way of the multiples of thousands of several comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a traditional battleground, or some may say cult stock. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *